Eli Lilly Defends Its Trademark Turf While Expanding into Gene Editing
Jun/17/2025
Even as Eli Lilly deepens its foray into cutting-edge cardiovascular therapies—underscored by its recent $1.3 billion acquisition of gene-editing pioneer Verve Therapeutics—the pharmaceutical heavyweight has remained equally assertive in protecting its intellectual property. In four separate rulings from WIPO, Lilly prevailed against domain squatters exploiting its high-profile brands, notably MOUNJARO and ZEPBOUND. The disputed domains — <imounjaroo.life>, <canetamonjaro.site>, <mounjaroku.com>, <lillyzepboundonline.com>, and <mounjaroofficial.com> — were all found to have mimicking Lilly trademarks. Panelists noted the respondents’ repeated use of modifiers such as 'official', 'online', and geographical hints to create an illusion of legitimacy, while directing traffic to sites offering unregulated pharmaceuticals or even rival products. The rulings not only reaffirm Lilly’s global trademark rights but also highlight the reputational and safety risks associated with online drug counterfeiting. As the firm accelerates its ambitions in gene therapies — with Verve’s base - editing platform and its lead PCSK9-targeting candidate VERVE-102 promising a one-time, potentially curative treatment for high cholesterol — its dual strategy of innovation and aggressive brand enforcement underscores the stakes in both reputation management and therapeutic leadership. Analysts suggest the acquisition marks a timely vote of confidence in the gene-editing sector, which has recently faced investor skepticism.
Latest Highlights
-
General Electric Prevails in Domain Dispute
May/14/2025
